Published in Biochem J on July 15, 1996
Lifting the lid on GPCRs: the role of extracellular loops. Br J Pharmacol (2012) 1.50
Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression. Biochem J (2001) 0.84
Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation. Br J Pharmacol (1999) 0.77
Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators. Biophys J (2004) 0.77
Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility. Hum Reprod (2013) 0.77
Structure and function of G protein-coupled receptors. Annu Rev Biochem (1994) 3.36
Molecular cloning of the receptor for human antidiuretic hormone. Nature (1992) 2.44
Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature (1992) 2.37
A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature (1994) 2.30
Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin. Biochem Soc Trans (1979) 2.12
Structure and expression of a human oxytocin receptor. Nature (1992) 2.06
Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature (1992) 1.84
Structure and function of receptors coupled to G proteins. Curr Opin Cell Biol (1994) 1.82
Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature (1994) 1.43
Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem (1994) 1.35
A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. Nature (1993) 1.34
Partial functional mapping of the human interleukin-8 type A receptor. Identification of a major ligand binding domain. J Biol Chem (1993) 1.30
Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet (1994) 1.30
Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem (1993) 1.21
Different binding epitopes on the NK1 receptor for substance P and non-peptide antagonist. Nature (1993) 1.21
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J (1995) 1.19
Amino-aromatic interaction between histidine 197 of the neurokinin-1 receptor and CP 96345. Nature (1993) 1.16
The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J Biol Chem (1995) 1.11
Structure, function, and phylogeny of [Arg8]vasotocin receptors from teleost fish and toad. Proc Natl Acad Sci U S A (1994) 1.10
Peptide receptors. Stepping up the pressure. Nature (1992) 1.09
An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system. Mol Endocrinol (1994) 1.02
Intronic nature of the rat luteinizing hormone receptor gene defines a soluble receptor subspecies with hormone binding activity. J Biol Chem (1990) 0.96
Human choriogonadotropin binds to a lutropin receptor with essentially no N-terminal extension and stimulates cAMP synthesis. J Biol Chem (1991) 0.95
The extracellular domain of the neurokinin-1 receptor is required for high-affinity binding of peptides. Biochemistry (1992) 0.95
Purification of hepatocyte couplets by centrifugal elutriation. Hepatology (1991) 0.91
Direct identification of an extracellular agonist binding site in the renal V2 vasopressin receptor. Biochemistry (1993) 0.91
Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem Biophys Res Commun (1994) 0.90
Molecular pharmacology of V1a vasopressin receptors. Gen Pharmacol (1995) 0.87
Fluorescent and biotinylated linear peptides as selective bifunctional ligands for the V1a vasopressin receptor. Eur J Biochem (1993) 0.87
Identification of hormone-binding regions of the luteinizing hormone/human chorionic gonadotropin receptor using synthetic peptides. Endocrinology (1992) 0.85
Localization and synthesis of the hormone-binding regions of the human thyrotropin receptor. Proc Natl Acad Sci U S A (1991) 0.84
Homology between neurohypophyseal hormone receptors. Biochem J (1993) 0.82
Identification of a domain of ETA receptor required for ligand binding. FEBS Lett (1992) 0.78
Cell receptors as drugs. Ligand binding domains of receptors as drugs: a potential new class of therapeutic agents. J R Coll Physicians Lond (1991) 0.77
A synthetic peptide corresponding to amino acids 9-30 of the extracellular domain of the follitropin (FSH) receptor specifically binds FSH. Mol Cell Endocrinol (1992) 0.77
Drug design. Reflections on a peptide. Nature (1994) 0.77
Structural and functional characterization of the human formyl peptide receptor ligand-binding region. Infect Immun (1994) 0.76
Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci (1996) 3.31
Role of perivenous areolar tissue and recipient bed in the viability of venous flaps in the rabbit ear model. Br J Plast Surg (1994) 1.37
Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat (2011) 1.36
Propylbenzilylcholine mustard labels an acidic residue in transmembrane helix 3 of the muscarinic receptor. J Biol Chem (1989) 1.15
The third extracellular loop of G-protein-coupled receptors: more than just a linker between two important transmembrane helices. Biochem Soc Trans (2004) 0.98
Lentiviral transduction of green fluorescent protein in retinal epithelium: evidence of rejection. Vision Res (2002) 0.95
Growth of normal human hepatocytes in primary culture: effect of hormones and growth factors on DNA synthesis. Hepatology (1991) 0.94
Palmitoylation of the vasopressin V1a receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation, and sequestration. J Biol Chem (2001) 0.91
Curcumin: a new cell-permeant inhibitor of the inositol 1,4,5-trisphosphate receptor. Cell Calcium (2002) 0.89
Peptide mapping studies on muscarinic receptors: receptor structure and location of the ligand binding site. Trends Pharmacol Sci (1988) 0.89
Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med (2006) 0.88
Molecular pharmacology of V1a vasopressin receptors. Gen Pharmacol (1995) 0.87
Fluorescent and biotinylated linear peptides as selective bifunctional ligands for the V1a vasopressin receptor. Eur J Biochem (1993) 0.87
Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin. Biochem Soc Trans (2004) 0.87
Atopy and asthma in rural Poland: a paradigm for the emergence of childhood respiratory allergies in Europe. Allergy (2007) 0.86
Ligand binding and activation of the CGRP receptor. Biochem Soc Trans (2007) 0.85
Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression. Biochem J (2001) 0.84
Chimeric strategies for the rational design of bioactive analogs of small peptide hormones. FASEB J (1997) 0.84
Muscarinic receptor subtypes and the selectivity of agonists and antagonists. Pharmacology (1988) 0.82
Homology between neurohypophyseal hormone receptors. Biochem J (1993) 0.82
Rat testicular myoid cells express vasopressin receptors: receptor structure, signal transduction, and developmental regulation. Endocrinology (1995) 0.81
Do vasopressin receptors have a significant role in the hormonal regulation of human liver function? Biochem Soc Trans (1990) 0.80
Interaction of calcitonin-gene-related peptide with its receptors. Biochem Soc Trans (2002) 0.80
Biochemical mechanisms of calcium mobilisation induced by mastoparan and chimeric hormone-mastoparan constructs. Cell Calcium (1998) 0.80
Purification of the muscarinic acetylcholine receptor from rat forebrain. Biochem Soc Trans (1985) 0.79
Renal bradykinin and vasopressin receptors: ligand selectivity and classification. Kidney Int (1996) 0.79
Soluble and membrane-bound muscarinic acetylcholine receptors. Biochem Soc Symp (1986) 0.79
Binding and hydrodynamic properties of muscarinic receptor subtypes solubilized in 3-(3-cholamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate. Mol Pharmacol (1989) 0.79
Reconstitution of solubilised brain D2 dopamine receptors into phospholipid vesicles. FEBS Lett (1984) 0.79
Selective amygdalohippocampectomy: surgical outcome in children versus adults. Can J Neurol Sci (2009) 0.79
Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus. Biochemistry (2000) 0.79
Localization and structure of the muscarinic receptor ligand binding site. Trends Pharmacol Sci (1989) 0.78
Localisation of arginine vasopressin V1a receptors on sympatho-adrenal preganglionic neurones. Exp Brain Res (1998) 0.78
Pathology and neuroimaging in pediatric temporal lobectomy for intractable epilepsy. Pediatr Neurosurg (2001) 0.78
A selective biotinylated probe for V1a vasopressin receptors. Mol Cell Endocrinol (1991) 0.78
Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes. Biochem J (2001) 0.77
Characterisation of brain D2 dopamine receptors solubilised by lysophosphatidylcholine. FEBS Lett (1983) 0.77
The structure and properties of the purified muscarinic acetylcholine receptor from rat forebrain. Biochem Soc Trans (1987) 0.77
Novel strategies for the design of receptor-selective vasopressin analogues: Aib-substitution and retro-inverso transformation. Br J Pharmacol (1999) 0.77
Pharmacological characterization of linear analogues of vasopressin generated by the systematic substitution of positions 1 and 6 by L-amino acids. Biochem Pharmacol (1994) 0.76
Solubilization of brain dopamine receptors. Adv Biochem Psychopharmacol (1983) 0.76
Effects of vasopressin-mastoparan chimeric peptides on insulin release and G-protein activity. Regul Pept (1999) 0.76
Pediatric temporal lobectomy for epilepsy. Pediatr Neurosurg (2003) 0.76
Intramedullary blood vessels of the spinal cord express V1a vasopressin receptors: visualization by a biotinylated ligand. Neuroendocrinology (1995) 0.76
Design and synthesis of heterofunctional V1a-selective vasopressin receptor ligands with lysine at position 9. J Mol Endocrinol (1992) 0.76
Characterization of G protein-coupled receptors expressed by ECV304 human endothelial cells. Endothelium (1998) 0.76
Corneal ulcers in patients with Apert syndrome. J Craniofac Surg (2001) 0.75
The team's the thing. Nurs Manag (Harrow) (1996) 0.75
Clinical ladders? Yes! Nurs Adm Q (1984) 0.75
The importance of acidic amino acid residues in the binding of ligands to the V1a vasopressin receptor. Biochem Soc Trans (1995) 0.75
Chimeric analogues of vasopressin and bradykinin. Biochem Soc Trans (1997) 0.75
Characterization of an epitope-tagged vasopressin V1a receptor: a probe for receptor structure and function. Biochem Soc Trans (1997) 0.75
Building up the foundation of rehabilitation. Health Soc Serv J (1979) 0.75
Defining the ligand-binding site for vasopressin receptors: a peptide mimetic approach. Biochem Soc Trans (1995) 0.75
Nurses on board. Nurs Manag (Harrow) (1999) 0.75
Visualization of oxytocin receptors using selective biotinylated probes. Biochem Soc Trans (1997) 0.75
Probing the V1a vasopressin receptor binding site with pyroglutamate-substituted linear antagonists. Neuropeptides (1996) 0.75
The role of putative glycosylation sites in the extracellular loops of the vasopressin V1a receptor. Biochem Soc Trans (1997) 0.75
An easy method to remove retinal biopsy specimens from the eye. Retina (2000) 0.75
Improvement in conditions for solubilisation and characterisation of brain D2 dopamine receptors using various detergents. J Neurochem (1984) 0.75
Muscarinic acetylcholine receptors: structure, function subtypes and therapeutic perspectives. Postgrad Med J (1987) 0.75
Family resemblances? Ligand binding and activation of family A and B G-protein-coupled receptors. Biochem Soc Trans (2007) 0.75
Novel vasopressin receptor ligands. Biochem Soc Trans (1991) 0.75
Hepatic vasopressin receptors (VPRs) exhibit species heterogeneity--absence of VPRs in sheep liver. Comp Biochem Physiol C (1993) 0.75
Structure/function studies of the human oxytocin receptor by site-directed mutagenesis. Adv Exp Med Biol (1995) 0.75
Human liver vasopressin receptors. Clin Chim Acta (1991) 0.75
Use of the radial forearm free tissue flap to treat persistent stricture after esophagogastrectomy. Am J Surg (2001) 0.75
Characterization of the human oxytocin receptor ligand binding site. Biochem Soc Trans (1997) 0.75
Calcium-mobilizing actions of chimeric hormone-mastoparan peptides. Biochem Soc Trans (1997) 0.75
Risk of blood contact through surgical gloves in aesthetic procedures. Aesthetic Plast Surg (1993) 0.75
Chimeric hormones and neuropeptides. Clin Sci (Lond) (1997) 0.75
Synthesis and characterization of tagged human oxytocin receptors (hOTRs). Biochem Soc Trans (1998) 0.75